Repligen (NASDAQ:RGEN) Earns Peer Perform Rating from Analysts at Wolfe Research

Stock analysts at Wolfe Research assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued to clients and investors on Thursday,Briefing.com Automated Import reports. The firm set a “peer perform” rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the company. Royal Bank of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Finally, UBS Group cut their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $150.47 on Thursday. The stock has a market cap of $8.43 billion, a PE ratio of -406.66, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The stock has a fifty day moving average of $141.59 and a 200-day moving average of $144.78.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.23 earnings per share. Equities research analysts anticipate that Repligen will post 1.45 earnings per share for the current year.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after purchasing an additional 21,719 shares during the last quarter. Champlain Investment Partners LLC grew its holdings in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after acquiring an additional 850,345 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC grew its holdings in shares of Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after acquiring an additional 199,322 shares during the period. Finally, Thrivent Financial for Lutherans grew its holdings in shares of Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after acquiring an additional 36,773 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.